Showing 1761-1770 of 3038 results for "".
- EyeCare Partners Expands Footprint in Northern Ohio with Three Additional Practiceshttps://modernod.com/news/eyecare-partners-expands-footprint-in-northern-ohio-with-three-additional-practices/2481171/EyeCare Partners announced that it has expanded its presence in Northern Ohio through a partnership with Novus Clinic, Corrective Eye Center, and Retina Specialists of Ohio (RSO). Additionally, the company plans to build a new Ambulatory Surgery Center (ASC) as well as a 16-exam lane clinic,
- Harrow Sells Non-Ophthalmic Compounding Businesshttps://modernod.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/Harrow announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation. Financial terms of the deal were not disclosed. Revelation purchased the assets of Harrow’s non‑ophthalmic c
- NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopiahttps://modernod.com/news/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/2481148/NovaSight announced that the FDA has cleared CureSight, a digital therapy device for amblyopia (lazy eye). CureSight is an eye-tracking-based system aimed for improving visual acuity and stereo acuity by training the visual system to use both eyes simultaneously. The ground-breaking cle
- Haag-Streit to Host a Series of Educational Webinars as Part of its Biometry Focus Month in Novemberhttps://modernod.com/news/haag-streit-to-host-a-series-of-educational-webinars-as-part-of-its-biometry-focus-month-in-november/2481139/Haag-Streit will host a variety of educational webinars as part of its Biometry Focus Month in November. This series of webinars will be delivered by a distinguished faculty consisting of notable key opinion leaders, complemented by Haag-Streit biometry product specialists. Hosted on Zo
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- Iridex to Showcase its Non-Incisional Treatments for Glaucoma and Introduce Sweep Management Software at AAO 2022https://modernod.com/news/iridex-to-showcase-its-non-incisional-treatments-for-glaucoma-and-introduce-sweep-management-software-at-aao-2022/2481130/Iridex will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software, and host 8 physician presentations at the 2022 American Academy of Ophthalmology (AAO) annual meeting in Chicago, September 30 – October 3. MicroPulse Transscleral Laser Thera
- Samsung Bioepis Presents Data from its Ophthalmology Biosimilar Portfolio at AAO 2022 Annual Meetinghttps://modernod.com/news/samsung-bioepis-presents-data-from-its-ophthalmology-biosimilar-portfolio-at-aao-2022-annual-meeting/2481121/Samsung Bioepis announced that three scientific abstracts relating to its ophthalmology biosimilar portfolio will be presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held from September 30 to October 3, 2022 in Chicago. The phase 3 study on SB15, a
- Bausch + Lomb and Novaliq Announce FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-filing-acceptance-for-investigational-treatment-nov03-perfluorohexyloctane/2481063/Bausch + Lomb and Novaliq announced that the FDA has accepted the new drug application (NDA) filing for investigational treatment NOV03 (perfluorohexyloctane). A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs an
- Nova Eye Medical Announces Global Data Registry to Support Role of Canaloplasty for Glaucomahttps://modernod.com/news/nova-eye-medical-announces-global-data-registry-to-support-role-of-canaloplasty-for-glaucoma/2481014/Nova Eye Medical announced the establishment of the iTrack Global Data Registry to collect prospective, multicenter, longitudinal data for canaloplasty in the treatment of glaucoma. A collaboration with the International Glaucoma Surgery Registry (IGSR), the iTrack Global
- NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova Lid and Lash Spray for Lash Extensionshttps://modernod.com/news/novabay-pharmaceuticals-targets-new-market-with-antimicrobial-avenova-lid-and-lash-spray-for-lash-extensions/2480997/NovaBay Pharmaceuticals announced the launch of a new marketing campaign targeting the large and growing number of women who wear eyelash extensions. This campaign represents the first step in a larger growth initiative to introduce the Avenova brand to an new group of consumers.</